# A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

> **NCT03785184** · PHASE2 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** venetoclax
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT03785184
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-04-29
- **Primary completion:** 2019-08-22
- **Final completion:** 2019-08-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785184, "A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03785184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*